Shiraishi Jin, Itoh Shinji, Tomino Takahiro, Yoshiya Shohei, Nagao Yoshihiro, Morita Kazutoyo, Kayashima Hiroto, Harada Noboru, Ichiki Yasunori, Yoshizumi Tomoharu
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Department of Internal Medicine, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, 806-8501, Japan.
J Surg Case Rep. 2023 Aug 26;2023(8):rjad485. doi: 10.1093/jscr/rjad485. eCollection 2023 Aug.
Surgical therapy following lenvatinib (LEN) plus transarterial chemoembolization (TACE) is a useful therapeutic option for intermediate-stage hepatocellular carcinoma (HCC). A 66-year-old man with a history of hepatitis C was detected four masses in the caudate lobe and segment 6/7 of the liver, with a maximum lesion diameter of 14 cm by computed tomography. The patient was diagnosed with intermediate-stage HCC and received LEN plus TACE. After resuming LEN for 8 weeks, computed tomography showed weakened stained areas of the tumors, and no new lesions. Thus, the patient was evaluated as having a partial response in the modified Response Evaluation Criteria in Solid Tumors. The patient underwent hepatic caudate lobectomy, partial hepatectomy of S6/7, and S6 microwave coagulation therapy for radical resection. The patient is currently alive and recurrence-free at 12 months postoperatively. In patients with multiple HCC lesions, hepatic resection combined with local therapy might be an effective treatment option.
乐伐替尼（LEN）联合经动脉化疗栓塞术（TACE）后行手术治疗是中期肝细胞癌（HCC）的一种有效治疗选择。一名66岁有丙型肝炎病史的男性患者，通过计算机断层扫描在肝尾状叶及肝6/7段发现4个肿块，最大病变直径为14厘米。该患者被诊断为中期HCC，并接受了LEN联合TACE治疗。恢复使用LEN 8周后，计算机断层扫描显示肿瘤染色区域变淡，且无新病变。因此，根据实体瘤改良疗效评价标准，该患者被评估为部分缓解。患者接受了肝尾状叶切除术、S6/7段部分肝切除术及S6段微波凝固治疗以进行根治性切除。患者目前术后12个月仍存活且无复发。对于有多发性HCC病变的患者，肝切除联合局部治疗可能是一种有效的治疗选择。
